Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy

Hongxi Wu, Yan Li, Guangjiang Shi, Shijia Du, Xiaobin Wang, Wanli Ye, Zixuan Zhang, Ya Chu, Shuqian Ma, Dajia Wang, Yuan Li, Zhen Chen, Lutz Birnbaumer, Zhuo Wang, Yong Yang – 5 January 2022

Noninvasive Prediction of Outcomes in Autoimmune Hepatitis–Related Cirrhosis

Laura‐Patricia Llovet, Jordi Gratacós‐Ginès, Luis Téllez, Ana Gómez‐Outomuro, Carmen A. Navascués, Mar Riveiro‐Barciela, Raquel Vinuesa, Judith Gómez‐Camarero, Montserrat García‐Retortillo, Fernando Díaz‐Fontenla, Magdalena Salcedo, María García‐Eliz, Diana Horta, Marta Guerrero, Manuel Rodríguez‐Perálvarez, Conrado Fernández‐Rodriguez, Agustín Albillos, Juan G‐Abraldes, Albert Parés, Maria‐Carlota Londoño – 5 January 2022 – The value of noninvasive tools in the diagnosis of autoimmune hepatitis (AIH)–related cirrhosis and the prediction of clinical outcomes is largely unknown.

Surgical Outcomes of Domino Liver Transplantation Using Grafts From Living Donors With Familial Amyloid Polyneuropathy

Hidekazu Yamamoto, Yuzuru Sambommatsu, Masatsugu Ishii, Keita Shimata, Kaori Isono, Masaki Honda, Yasuhiko Sugawara, Yukihiro Inomata, Taizo Hibi – 5 January 2022 – Domino liver transplantation (DLT) using grafts from donors with familial amyloid polyneuropathy is an acceptable procedure for expanding the donor pool. The vascular and biliary reconstructions in living donor DLT (LDDLT) are technically demanding, and data on the short‐term and long‐term surgical outcomes of domino donors and recipients in LDDLT are limited.

Getting to HBV cure: The promising paths forward

Scott Fung, Hannah S. J. Choi, Adam Gehring, Harry L. A. Janssen – 5 January 2022 – Chronic HBV infection is a global public health burden estimated to impact nearly 300 million persons worldwide. Despite the advent of potent antiviral agents that effectively suppress viral replication, HBV cure remains difficult to achieve because of the persistence of covalently closed circular DNA (cccDNA), HBV‐DNA integration into the host genome, and impaired immune response. Indefinite treatment is necessary for most patients to maintain level of viral suppression.

Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis

Cheng Han Ng, Jieling Xiao, Wen Hui Lim, Yip Han Chin, Jie Ning Yong, Darren Jun Hao Tan, Phoebe Tay, Nicholas Syn, Roger Foo, Mark Chan, Nicholas Chew, Eunice XX Tan, Daniel Q. Huang, Yock Young Dan, Nobuharu Tamaki, Mohammad Shadab Siddiqui, Arun J. Sanyal, Rohit Loomba, Mazen Noureddin, Mark D. Muthiah – 5 January 2022

Patient‐reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Marina Serper, Neehar D. Parikh, Grace Thiele, Nadia Ovchinsky, Shivang Mehta, Alexander Kuo, Chanda Ho, Fasiha Kanwal, Michael Volk, Sumeet K. Asrani, Marwan S. Ghabril, John R. Lake, Raphael B. Merriman, Timothy R. Morgan, Elliot B. Tapper – 5 January 2022

Development of Alcohol‐Associated Hepatitis Is Associated With Specific Changes in Gut‐Modified Bile Acids

Mark D. Muthiah, Ekaterina Smirnova, Puneet Puri, Naga Chalasani, Vijay H. Shah, Calvin Kiani, Stephanie Taylor, Faridoddin Mirshahi, Arun J. Sanyal – 3 January 2022 – The perturbations in bile acids (BAs) in alcohol‐associated hepatitis (AH) and its relationship to disease severity is not well defined. The aims of this study were to define (1) the effects of heavy alcohol consumption on BAs and related microbiome, (2) the additional changes with AH, and (3) the relationship of these changes to disease severity.

Subscribe to